guest ::
| Home > Publications database > IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma. > print |
| Home > Publications database > IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma. > print |
| 001 | 181140 | ||
| 005 | 20240229145641.0 | ||
| 024 | 7 | _ | |a 10.1007/s00432-022-04277-7 |2 doi |
| 024 | 7 | _ | |a pmid:35963900 |2 pmid |
| 024 | 7 | _ | |a 0084-5353 |2 ISSN |
| 024 | 7 | _ | |a 0171-5216 |2 ISSN |
| 024 | 7 | _ | |a 0943-9382 |2 ISSN |
| 024 | 7 | _ | |a 1432-1335 |2 ISSN |
| 024 | 7 | _ | |a altmetric:140491594 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01793 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Struckmeier, Ann-Kristin |0 0000-0002-4015-1466 |b 0 |
| 245 | _ | _ | |a IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma. |
| 260 | _ | _ | |a Berlin |c 2023 |b Springer |
| 264 | _ | 1 | |3 online |2 Crossref |b Springer Science and Business Media LLC |c 2022-08-13 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1688562156_17043 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Jul;149(7):3623-3635 |
| 520 | _ | _ | |a Strategies for Indolamine-2,3-dioxygenase 1 (IDO1) inhibition in cancer immunotherapy once produced encouraging results, but failed in clinical trials. Recent evidence indicates that immune cells in the tumour microenvironment, especially macrophages, contribute to immune dysregulation and therefore might play a critical role in drug resistance.In this study, we investigated the significance of IDO1 expressing immune cells in primary tumours and corresponding lymph node metastases (LNMs) in oral squamous cell carcinoma (OSCC) by immunohistochemistry. The link between IDO1 and macrophages was investigated by flow cytometry in tumour tissue, healthy adjacent tissue and peripheral blood mononuclear cells (PBMCs). IDO1 activity (measured as Kynurenine/Tryptophan ratio) was assessed by ELISAs.High IDO1 expression in tumour-infiltrating immune cells was significantly correlated with advanced stages [Spearman's rank correlation (SRC), p = 0.027] and reduced progression-free survival (multivariate Cox regression, p = 0.034). IDO1 was significantly higher expressed in PBMCs of patients in advanced stages than in healthy controls (ANOVA, p < 0.05) and IDO1+ macrophages were more abundant in intratumoural areas than peritumoural (t test, p < 0.001). IDO1 expression in PBMCs was significantly correlated with IDO1 activity in serum (SRC, p < 0.05). IDO1 activity was significantly higher in patients with LNMs (t test, p < 0.01).All in all, IDO1 expressing immune cells, especially macrophages, are more abundant in advanced stages of OSCC and are associated with reduced progression-free survival. Further investigations are needed to explore their role in local and systemic immune response. The IDO1 activity might be a suitable biomarker of metastasis in OSCC patients. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 542 | _ | _ | |i 2022-08-13 |2 Crossref |u https://creativecommons.org/licenses/by/4.0 |
| 542 | _ | _ | |i 2022-08-13 |2 Crossref |u https://creativecommons.org/licenses/by/4.0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a IDO |2 Other |
| 650 | _ | 7 | |a Immunotherapy |2 Other |
| 650 | _ | 7 | |a Macrophage |2 Other |
| 650 | _ | 7 | |a Oral squamous cell carcinoma (OSCC) |2 Other |
| 650 | _ | 7 | |a Tumour microenvironment |2 Other |
| 700 | 1 | _ | |a Radermacher, Anne |b 1 |
| 700 | 1 | _ | |a Fehrenz, Michael |b 2 |
| 700 | 1 | _ | |a Bellin, Tamara |b 3 |
| 700 | 1 | _ | |a Alansary, Dalia |b 4 |
| 700 | 1 | _ | |a Wartenberg, Philipp |b 5 |
| 700 | 1 | _ | |a Boehm, Ulrich |b 6 |
| 700 | 1 | _ | |a Wagner, Mathias |b 7 |
| 700 | 1 | _ | |a Scheller, Anja |b 8 |
| 700 | 1 | _ | |a Hess, Jochen |0 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f |b 9 |u dkfz |
| 700 | 1 | _ | |a Moratin, Julius |b 10 |
| 700 | 1 | _ | |a Freudlsperger, Christian |b 11 |
| 700 | 1 | _ | |a Hoffmann, Jürgen |b 12 |
| 700 | 1 | _ | |a Thurner, Lorenz |b 13 |
| 700 | 1 | _ | |a Roemer, Klaus |b 14 |
| 700 | 1 | _ | |a Freier, Kolja |b 15 |
| 700 | 1 | _ | |a Horn, Dominik |b 16 |
| 773 | 1 | 8 | |a 10.1007/s00432-022-04277-7 |b Springer Science and Business Media LLC |d 2022-08-13 |3 journal-article |2 Crossref |t Journal of Cancer Research and Clinical Oncology |y 2022 |x 0171-5216 |
| 773 | _ | _ | |a 10.1007/s00432-022-04277-7 |0 PERI:(DE-600)1459285-X |n 7 |p 3623-3635 |t Journal of cancer research and clinical oncology |v 149 |y 2023 |x 0171-5216 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:181140 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J CANCER RES CLIN : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)E221-20160331 |k E221 |l Molekulare Grundlagen von HNO-Tumoren |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E221-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1111/jop.12643 |9 -- missing cx lookup -- |1 AM Alves |p 460 - |2 Crossref |u Alves AM, Diel L, Lamers M (2018) Macrophages and prognosis of oral squamous cell carcinoma: a systemic review. J Oral Pathol Med 47:460–467 |t J Oral Pathol Med |v 47 |y 2018 |
| 999 | C | 5 | |a 10.1177/1178646919868978 |9 -- missing cx lookup -- |1 AA Badawy |p 117864691986897 - |2 Crossref |u Badawy AA, Guillemin G (2019) The plasma [kynurenine]/[tryptophan] ratio and indoleamine 2,3-dioxygenase: time for appraisal. Int J Tryptophan Res 12:1178646919868978. https://doi.org/10.1177/1178646919868978 |t Int J Tryptophan Res |v 12 |y 2019 |
| 999 | C | 5 | |a 10.1016/j.imlet.2015.11.012 |9 -- missing cx lookup -- |1 A Ben-Haj-Ayed |p 23 - |2 Crossref |u Ben-Haj-Ayed A, Moussa A, Ghedira R, Gabbouj S, Miled S, Bouzid N, Tebra-Mrad S, Bouaouina N, Chouchane L, Zakhama A, Hassen E (2016) Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma. Immunol Lett 169:23–32. https://doi.org/10.1016/j.imlet.2015.11.012 |t Immunol Lett |v 169 |y 2016 |
| 999 | C | 5 | |a 10.1016/j.jcms.2017.01.033 |9 -- missing cx lookup -- |1 S Blatt |p 722 - |2 Crossref |u Blatt S, Krüger M, Ziebart T, Sagheb K, Schiegnitz E, Goetze E, Al-Nawas B, Pabst AM (2017) Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: a review of the literature. J Craniomaxillofac Surg 45:722–730. https://doi.org/10.1016/j.jcms.2017.01.033 |t J Craniomaxillofac Surg |v 45 |y 2017 |
| 999 | C | 5 | |a 10.1016/j.ejca.2017.01.011 |9 -- missing cx lookup -- |1 F Bray |p 167 - |2 Crossref |u Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, Brochez L, Chevolet I, Kruse V (2017) The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 76:167–182. https://doi.org/10.1016/j.ejca.2017.01.011 |t Eur J Cancer |v 76 |y 2017 |
| 999 | C | 5 | |a 10.1016/j.ejca.2017.01.011 |9 -- missing cx lookup -- |1 L Brochez |p 167 - |2 Crossref |u Brochez L, Chevolet I, Kruse V (2017) The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 76:167–182. https://doi.org/10.1016/j.ejca.2017.01.011 |t Eur J Cancer |v 76 |y 2017 |
| 999 | C | 5 | |a 10.3390/cancers6031670 |9 -- missing cx lookup -- |1 T Chanmee |p 1670 - |2 Crossref |u Chanmee T, Ontong P, Konno K, Itano N (2014) Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 6:1670–1690. https://doi.org/10.3390/cancers6031670 |t Cancers |v 6 |y 2014 |
| 999 | C | 5 | |a 10.4161/2162402X.2014.982382 |1 I Chevolet |9 -- missing cx lookup -- |2 Crossref |u Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, Brochez L (2015) Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology 4:e982382. https://doi.org/10.4161/2162402X.2014.982382 |t Oncoimmunology |v 4 |y 2015 |
| 999 | C | 5 | |a 10.1186/1471-2407-14-335 |9 -- missing cx lookup -- |1 JY Choe |p 335 - |2 Crossref |u Choe JY, Yun JY, Jeon YK, Kim SH, Park G, Huh JR, Oh S, Kim JE (2014) Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer 14:335. https://doi.org/10.1186/1471-2407-14-335 |t BMC Cancer |v 14 |y 2014 |
| 999 | C | 5 | |a 10.1038/nature13490 |9 -- missing cx lookup -- |1 OR Colegio |p 559 - |2 Crossref |u Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R (2014) Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513:559–563. https://doi.org/10.1038/nature13490 |t Nature |v 513 |y 2014 |
| 999 | C | 5 | |a 10.1136/esmoopen-2019-000646 |1 P Economopoulou |9 -- missing cx lookup -- |2 Crossref |u Economopoulou P, Kladi-Skandali A, Strati A, Koytsodontis G, Kirodimos E, Giotakis E, Maragoudakis P, Gagari E, Maratou E, Dimitriadis G, Kotsantis I, Vagia E, Anastasiou M, Gkotzamanidou M, Kavourakis G, Lianidou E, Psyrri A (2020) Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma. ESMO Open 5:e000646. https://doi.org/10.1136/esmoopen-2019-000646 |t ESMO Open |v 5 |y 2020 |
| 999 | C | 5 | |a 10.1038/bjc.2011.513 |9 -- missing cx lookup -- |1 L Ferdinande |p 141 - |2 Crossref |u Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu AM, Van Maerken T, Salmon I, Cuvelier CA, Demetter P (2012) Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 106:141–147. https://doi.org/10.1038/bjc.2011.513 |t Br J Cancer |v 106 |y 2012 |
| 999 | C | 5 | |1 K Freier |y 2003 |2 Crossref |u Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, Lichter P, Hofele C (2003) Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 63:1179–1182 |
| 999 | C | 5 | |1 RM Giusti |y 1996 |2 Crossref |u Giusti RM, Maloney EM, Hanchard B, Morgan OS, Steinberg SM, Wachter H, Williams E, Cranston B, Fuchs D, Manns A (1996) Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prev 5:699–704 |
| 999 | C | 5 | |a 10.3322/caac.21492 |9 -- missing cx lookup -- |1 Global cancer statistics |p 394 - |2 Crossref |u Global cancer statistics (2018) (2018) GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 |t CA Cancer J Clin |v 68 |y 2018 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3389/fimmu.2020.00120 10.1111/jop.12643 |2 Crossref |u Herrera-Rios D, Mughal SS, Teuber-Hanselmann S, Pierscianek D, Sucker A, Jansen P, Schimming T, Klode J, Reifenberger J, Felsberg J, Keyvani K, Brors B, Sure U, Reifenberger G, Schadendorf D, Helfrich I (2020) Macrophages/microglia represent the major source of indolamine 2,3-dioxygenase expression in melanoma metastases of the brain. Front Immunol 11:120. https://doi.org/10.3389/fimmu.2020.00120. https://doi.org/10.1111/jop.12643 |
| 999 | C | 5 | |a 10.1038/sj.bjc.6600336 |9 -- missing cx lookup -- |1 A Huang |p 1691 - |2 Crossref |u Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG (2002) Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86:1691–1696. https://doi.org/10.1038/sj.bjc.6600336 |t Br J Cancer |v 86 |y 2002 |
| 999 | C | 5 | |a 10.1016/j.ygyno.2009.07.015 |9 -- missing cx lookup -- |1 T Inaba |p 185 - |2 Crossref |u Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F (2009) Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115:185–192. https://doi.org/10.1016/j.ygyno.2009.07.015 |t Gynecol Oncol |v 115 |y 2009 |
| 999 | C | 5 | |a 10.1111/j.1440-1746.2003.03259.x |9 -- missing cx lookup -- |1 T Ishio |p 319 - |2 Crossref |u Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S (2004) Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 19:319–326. https://doi.org/10.1111/j.1440-1746.2003.03259.x |t J Gastroenterol Hepatol |v 19 |y 2004 |
| 999 | C | 5 | |a 10.3390/cancers13184730 |9 -- missing cx lookup -- |1 JP Kühn |p 4730 - |2 Crossref |u Kühn JP, Schmid W, Körner S, Bochen F, Wemmert S, Rimbach H, Smola S, Radosa JC, Wagner M, Morris LGT, Bozzato V, Bozzato A, Schick B, Linxweiler M (2021) HPV status as prognostic biomarker in head and neck cancer-which method fits the best for outcome prediction? Cancers (basel) 13:4730. https://doi.org/10.3390/cancers13184730 |t Cancers (basel) |v 13 |y 2021 |
| 999 | C | 5 | |a 10.1016/j.oraloncology.2011.03.007 |9 -- missing cx lookup -- |1 K Laimer |p 352 - |2 Crossref |u Laimer K, Troester B, Kloss F, Schafer G, Obrist P, Perathoner A, Laimer J, Brandacher G, Rasse M, Margreiter R, Amberger A (2011) Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 47:352–357. https://doi.org/10.1016/j.oraloncology.2011.03.007 |t Oral Oncol |v 47 |y 2011 |
| 999 | C | 5 | |a 10.1002/cncy.21512 |9 -- missing cx lookup -- |1 M Linxweiler |p 219 - |2 Crossref |u Linxweiler M, Bochen F, Wemmert S, Lerner C, Hasenfus A, Bohle RM, Al-Kadah B, Takacs ZF, Smola S, Schick B (2015) Combination of p16(INK4a) /Ki67 immunocytology and HPV polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer. Cancer Cytopathol 123:219–229. https://doi.org/10.1002/cncy.21512 |t Cancer Cytopathol |v 123 |y 2015 |
| 999 | C | 5 | |a 10.1016/S1470-2045(19)30274-8 |9 -- missing cx lookup -- |1 GV Long |p 1083 - |2 Crossref |u Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC (2019) Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 20:1083–1097. https://doi.org/10.1016/S1470-2045(19)30274-8 |t Lancet Oncol |v 20 |y 2019 |
| 999 | C | 5 | |a 10.1158/2326-6066.CIR-13-0133 |9 -- missing cx lookup -- |1 AW MacFarlane 4th |p 320 - |2 Crossref |u MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS (2014) PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2:320–331. https://doi.org/10.1158/2326-6066.CIR-13-0133 |t Cancer Immunol Res |v 2 |y 2014 |
| 999 | C | 5 | |a 10.3390/ijms22094403 |9 -- missing cx lookup -- |1 M Mandarano |p 4403 - |2 Crossref |u Mandarano M, Orecchini E, Bellezza G, Vannucci J, Ludovini V, Baglivo S, Tofanetti FR, Chiari R, Loreti E, Puma F, Sidoni A, Belladonna ML (2021) Kynurenine/tryptophan ratio as a potential blood-based biomarker in non-small cell lung cancer. Int J Mol Sci 22:4403. https://doi.org/10.3390/ijms22094403 |t Int J Mol Sci |v 22 |y 2021 |
| 999 | C | 5 | |a 10.1002/cncr.20701 |9 -- missing cx lookup -- |1 B Marcus |p 2779 - |2 Crossref |u Marcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, Islam M, Paul S, Pan Q, Hanash S, Kuick R, Merajver SD, Teknos TN (2004) Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 101:2779–2787. https://doi.org/10.1002/cncr.20701 |t Cancer |v 101 |y 2004 |
| 999 | C | 5 | |a 10.3390/vaccines3030703 |9 -- missing cx lookup -- |1 JC Mbongue |p 703 - |2 Crossref |u Mbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge WH (2015) The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. Vaccines 3:703–729. https://doi.org/10.3390/vaccines3030703 |t Vaccines |v 3 |y 2015 |
| 999 | C | 5 | |a 10.1038/nri1457 |9 -- missing cx lookup -- |1 AL Mellor |p 762 - |2 Crossref |u Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762–774. https://doi.org/10.1038/nri1457 |t Nat Rev Immunol |v 4 |y 2004 |
| 999 | C | 5 | |a 10.1038/83183 |9 -- missing cx lookup -- |1 AL Mellor |p 64 - |2 Crossref |u Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, Munn DH (2001) Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2:64–68. https://doi.org/10.1038/83183 |t Nat Immunol |v 2 |y 2001 |
| 999 | C | 5 | |a 10.4049/jimmunol.164.12.6166 |9 -- missing cx lookup -- |1 CD Mills |p 6166 - |2 Crossref |u Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166–6173. https://doi.org/10.4049/jimmunol.164.12.6166 |t J Immunol |v 164 |y 2000 |
| 999 | C | 5 | |a 10.3892/etm.2018.5959 |9 -- missing cx lookup -- |1 K Minami |p 4465 - |2 Crossref |u Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S (2018) Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med 15:4465–4476. https://doi.org/10.3892/etm.2018.5959 |t Exp Ther Med |v 15 |y 2018 |
| 999 | C | 5 | |a 10.1002/hed.25713 |9 -- missing cx lookup -- |1 J Moratin |p 2484 - |2 Crossref |u Moratin J, Metzger K, Safaltin A, Herpel E, Hoffmann J, Freier K, Hess J, Horn D (2019) Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. Head Neck 41:2484–2491. https://doi.org/10.1002/hed.25713 |t Head Neck |v 41 |y 2019 |
| 999 | C | 5 | |a 10.1084/jem.189.9.1363 |9 -- missing cx lookup -- |1 DH Munn |p 1363 - |2 Crossref |u Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363–1372. https://doi.org/10.1084/jem.189.9.1363 |t J Exp Med |v 189 |y 1999 |
| 999 | C | 5 | |a 10.1126/science.1073514 |9 -- missing cx lookup -- |1 DH Munn |p 1867 - |2 Crossref |u Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL Jr, Mellor AL (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–1870. https://doi.org/10.1126/science.1073514 |t Science |v 297 |y 2002 |
| 999 | C | 5 | |a 10.4049/jimmunol.172.7.4100 |9 -- missing cx lookup -- |1 DH Munn |p 4100 - |2 Crossref |u Munn DH, Sharma MD, Mellor AL (2004) Ligation of B7–1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172:4100–4110. https://doi.org/10.4049/jimmunol.172.7.4100 |t J Immunol |v 172 |y 2004 |
| 999 | C | 5 | |a 10.1111/cas.13244 |9 -- missing cx lookup -- |1 T Ohashi |p 1128 - |2 Crossref |u Ohashi T, Aoki M, Tomita H, Akazawa T, Sato K, Kuze B, Mizuta K, Hara A, Nagaoka H, Inoue N, Ito Y (2017) M2-like macrophage polarization in high lactic acid-producing head and neck cancer. Cancer Sci 108:1128–1134. https://doi.org/10.1111/cas.13244 |t Cancer Sci |v 108 |y 2017 |
| 999 | C | 5 | |a 10.3389/fimmu.2020.583084 |1 Y Pan |9 -- missing cx lookup -- |2 Crossref |u Pan Y, Yu Y, Wang X, Zhang T (2020) Tumor-associated macrophages in tumor immunity. Front Immunol 11:583084. https://doi.org/10.3389/fimmu.2020.583084 |t Front Immunol |v 11 |y 2020 |
| 999 | C | 5 | |a 10.1158/1078-0432.CCR-07-0942 |9 -- missing cx lookup -- |1 R Riesenberg |p 6993 - |2 Crossref |u Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W (2007) Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 13:6993–7002. https://doi.org/10.1158/1078-0432.CCR-07-0942 |t Clin Cancer Res |v 13 |y 2007 |
| 999 | C | 5 | |a 10.1016/j.ccell.2015.02.015 |9 -- missing cx lookup -- |1 B Ruffell |p 462 - |2 Crossref |u Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27:462–472. https://doi.org/10.1016/j.ccell.2015.02.015 |t Cancer Cell |v 27 |y 2015 |
| 999 | C | 5 | |a 10.4049/jimmunol.0804328 |9 -- missing cx lookup -- |1 GN Scott |p 7509 - |2 Crossref |u Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L (2009) The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 182:7509–7517. https://doi.org/10.4049/jimmunol.0804328 |t J Immunol |v 182 |y 2009 |
| 999 | C | 5 | |a 10.3109/00016489.2016.1152631 |9 -- missing cx lookup -- |1 M Seppälä |p 729 - |2 Crossref |u Seppälä M, Halme E, Tiilikainen L, Luukkainen A, Laranne J, Rautiainen M, Huhtala H, Paavonen T, Toppila-Salmi S (2016) The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma. Acta Otolaryngol 136:729–735. https://doi.org/10.3109/00016489.2016.1152631 |t Acta Otolaryngol |v 136 |y 2016 |
| 999 | C | 5 | |a 10.1016/j.lungcan.2009.05.001 |9 -- missing cx lookup -- |1 Y Suzuki |p 361 - |2 Crossref |u Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67:361–365. https://doi.org/10.1016/j.lungcan.2009.05.001 |t Lung Cancer |v 67 |y 2010 |
| 999 | C | 5 | |a 10.1086/650996 |9 -- missing cx lookup -- |1 P Tattevin |p 956 - |2 Crossref |u Tattevin P, Monnier D, Tribut O, Dulong J, Bescher N, Mourcin F, Uhel F, Le Tulzo Y, Tarte K (2010) Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis 201:956–966. https://doi.org/10.1086/650996 |t J Infect Dis |v 201 |y 2010 |
| 999 | C | 5 | |a 10.1096/fasebj.5.11.1907934 |9 -- missing cx lookup -- |1 MW Taylor |p 2516 - |2 Crossref |u Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516–2522 |t FASEB J |v 5 |y 1991 |
| 999 | C | 5 | |a 10.1158/2326-6066.CIR-14-0137 |9 -- missing cx lookup -- |1 I Théate |p 161 - |2 Crossref |u Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ (2015) Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 3:161–172. https://doi.org/10.1158/2326-6066.CIR-14-0137 |t Cancer Immunol Res |v 3 |y 2015 |
| 999 | C | 5 | |a 10.18632/oncotarget.2110 |9 -- missing cx lookup -- |1 C Tripathi |p 5350 - |2 Crossref |u Tripathi C, Tewari BN, Kanchan RK, Baghel KS, Nautiyal N, Shrivastava R, Kaur H, Bhatt ML, Bhadauria S (2014) Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 5:5350–5368. https://doi.org/10.18632/oncotarget.2110 |t Oncotarget |v 5 |y 2014 |
| 999 | C | 5 | |a 10.1016/j.cell.2011.09.024 |9 -- missing cx lookup -- |1 S Valastyan |p 275 - |2 Crossref |u Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147:275–292. https://doi.org/10.1016/j.cell.2011.09.024 |t Cell |v 147 |y 2011 |
| 999 | C | 5 | |a 10.1186/1471-2407-14-522 |9 -- missing cx lookup -- |1 F Wehrhan |p 522 - |2 Crossref |u Wehrhan F, Büttner-Herold M, Hyckel P, Moebius P, Preidl R, Distel L, Ries J, Amann K, Schmitt C, Neukam FW, Weber M (2014) Increased malignancy of oral squamous cell carcinomas (oscc) is associated with macrophage polarization in regional lymph nodes—an immunohistochemical study. BMC Cancer 14:522. https://doi.org/10.1186/1471-2407-14-522 |t BMC Cancer |v 14 |y 2014 |
| 999 | C | 5 | |a 10.3389/fimmu.2020.01731 |9 -- missing cx lookup -- |1 K Wu |p 1731 - |2 Crossref |u Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, Xu D (2020) Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol 11:1731. https://doi.org/10.3389/fimmu.2020.01731 |t Front Immunol |v 11 |y 2020 |
| 999 | C | 5 | |a 10.1186/s13046-021-01847-4 |9 -- missing cx lookup -- |1 Y Yao |p 60 - |2 Crossref |u Yao Y, Liang H, Fang X, Zhang S, Xing Z, Shi L, Kuang C, Seliger B, Yang Q (2021) What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. J Exp Clin Cancer Res 40:60. https://doi.org/10.1186/s13046-021-01847-4 |t J Exp Clin Cancer Res |v 40 |y 2021 |
| 999 | C | 5 | |a 10.1007/s00428-012-1340-x |9 -- missing cx lookup -- |1 J Ye |p 73 - |2 Crossref |u Ye J, Liu H, Hu Y, Li P, Zhang G, Li Y (2013) Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch 462:73–81. https://doi.org/10.1007/s00428-012-1340-x |t Virchows Arch |v 462 |y 2013 |
| 999 | C | 5 | |a 10.1002/cac2.12001 |9 -- missing cx lookup -- |1 QH Zhou |p 3 - |2 Crossref |u Zhou QH, Han H, Lu JB, Liu TY, Huang KB, Deng CZ, Li ZS, Chen JP, Yao K, Qin ZK, Liu ZW, Li YH, Guo SJ, Ye YL, Zhou FJ, Liu RY (2020) Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients. Cancer Commun (lond) 40:3–15. https://doi.org/10.1002/cac2.12001 |t Cancer Commun (lond) |v 40 |y 2020 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|